MycoFold uses AI/ML-driven computational biology and engineered yeast to produce recombinant human growth factors and cytokines with enhanced bioactivity, thermal stability, and ease of reconstitution. Their first product, rHu M-CSF, is designed to deliver up to twice the specific activity of leading competitors, allowing labs to achieve equivalent results with up to 50% less reagent and at a lower list price.
Funding
Funding not disclosed
Founders
Product
Problem
Research laboratories routinely face high costs and inconsistent performance from commercially available recombinant cytokines and growth factors. Many existing products, particularly those expressed in E. coli or HEK-293 systems, suffer from poor folding, reduced thermal stability, and low specific bioactivity, forcing researchers to use excess reagent and spend more of their budget to achieve reliable experimental outcomes.
Solution
MycoFold leverages computational biology and engineered yeast expression systems to design and produce recombinant human growth factors and cytokines with maximum bioactivity and stability. Their proteins are engineered to present native structural motifs for optimal receptor binding and are manufactured to form correct disulfide bridges, resulting in superior pH and temperature resilience and simple reconstitution. The company's lead product, rHu M-CSF, delivers up to 2X the specific activity per IU compared to leading E. coli and HEK-293-based competitors, allowing researchers to use up to 50% less growth factor for equivalent differentiation results. This means labs achieve significantly more biological value per dollar spent on research reagents.
Target Audience
Primary customers are academic, biotech, and pharmaceutical research laboratories conducting cell culture, differentiation, and immunology studies that rely on recombinant human growth factors and cytokines such as M-CSF.
Features
- AI/ML-designed protein sequences engineered specifically for maximum bioactivity and structural fidelity
- Recombinant production in engineered yeast, yielding correctly folded proteins with native disulfide bridge formation
- Enhanced thermal stability with resilience to pH and temperature variations, simplifying storage and handling
- Demonstrated up to 2X higher specific activity per IU compared to leading E. coli (Competitor 1) and HEK-293 (Competitor 2) sourced M-CSF, verified via M-NFS-60 cell line (ATCC Cat. No. 30-2001) dose-response assays
- Lowest list price on M-CSF growth factors among major suppliers, reducing per-experiment costs
- Achieves up to 200% increase in bioactivity value per dollar spent compared to traditional products